The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Forecasted Market Value Of The Skyrizi Market Across 2026–2030?
Historical growth has been driven by an increase in autoimmune disorder diagnoses, the limitations of conventional immunosuppressive treatments, the growing adoption of biologics in dermatology and gastroenterology, expanded access to specialty care, and improved clinical trial success rates.
The projected growth during the forecast period is driven by expanding applications into new inflammatory conditions, increasing investments in advanced biologics, a rising patient preference for user-friendly dosing schedules, a growing healthcare focus on achieving lasting remission, and the broader incorporation of biologic treatments into guidelines.
Significant trends expected in the forecast period include the increasing uptake of IL-23 targeted therapies, their rising application across numerous autoimmune indications, a developing preference for biologics with extended dosing intervals, the wider availability of self-administered injectable formats, and a strengthened focus on sustained disease management.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20266&type=smp
What Drivers Are Shaping The Future Growth Of The Skyrizi Market?
The skyrizi market is anticipated to grow in the future, fueled by the increasing focus on personalized medicine. This medical approach involves customizing treatment and healthcare strategies to each patient’s unique characteristics, including their genetic makeup, environment, and lifestyle, to achieve the most effective and precise health outcomes. The expansion of personalized medicine is attributed to advancements in genomic technologies, a deeper understanding of molecular biology, the wider availability of precision diagnostic tools, and the demand for targeted therapies that enhance patient results while minimizing adverse effects. Skyrizi contributes to personalized medicine by offering a focused biologic therapy that specifically inhibits interleukin-23 (IL-23). This allows healthcare providers to tailor treatments for individuals with moderate to severe autoimmune conditions, such as psoriasis and ulcerative colitis, based on their specific responses and disease characteristics, thereby improving efficacy and reducing treatment-related side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Thus, the rising interest in personalized medicine significantly drives the skyrizi market.
What Segmentation Levels Are Considered In The Skyrizi Market?
The skyrizi market covered in this report is segmented –
1) By Indication: Plaque Psoriasis, Crohn’s Disease, Ulcerative Colitis
2) By Formulation: Pre-Filled Syringes, Vials
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
What Trends Are Projected To Affect The Skyrizi Market?
Leading companies in the SKYRIZI market are concentrating on developing innovative solutions, such as interleukin-23 (IL-23) inhibitor therapies, to address the increasing demand for targeted and highly effective treatments for autoimmune and chronic inflammatory conditions. IL-23 inhibitors operate by specifically blocking the p19 subunit of the IL-23 cytokine, which plays a pivotal role in driving inflammatory pathways. This focused methodology offers enhanced efficacy and safety compared to conventional broad-spectrum immunosuppressants. For instance, in July 2024, AbbVie Inc., a US-based biopharmaceutical company, obtained European Commission approval for SKYRIZI (risankizumab) for the management of adults with moderately to severely active ulcerative colitis who have not responded to, or are intolerant to, standard or biologic therapies. SKYRIZI is a monoclonal antibody that selectively inhibits IL-23, providing a precise mechanism of action that helps diminish inflammation and promote mucosal healing. The treatment protocol comprises a 1,200 mg IV induction regimen followed by 180 mg or 360 mg subcutaneous maintenance doses every eight weeks. Clinical evidence from the Phase 3 INSPIRE and COMMAND trials demonstrated robust outcomes, including significant mucosal healing and sustained remission, particularly in patients without prior biologic or JAK inhibitor use.
Which Leading Firms Are Contributing To The Growth Of The Skyrizi Market?
Major companies operating in the skyrizi market are AbbVie Inc.
Read the full skyrizi market report here:
https://www.thebusinessresearchcompany.com/report/skyrizi-global-market-report
Which Geographic Regions Are Influencing Demand In The Skyrizi Market?
North America was the largest region in the skyrizi market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the skyrizi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Skyrizi Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20266&type=smp
Browse Through More Reports Similar to the Global Skyrizi Market 2026, By The Business Research Company
Satellite Telecommunication Resellers Market Report 2026
Satellite Telecommunication Resellers Market Report 2026
Satellite Telecommunication Resellers Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model